Drugs / hAESCs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05435755 | Dec 2022 → Jul 2023 | Parkinson disease | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03381807 | Sep 2020 → Sep 2022 | adhesions of uterus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05691114 | Feb 2023 → Feb 2025 | Parkinson disease | Shanghai East Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hAESCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05435755 ↗ |
| Known as | Human amniotic epithelial stem cells | “Human amniotic epithelial stem cells (hAESCs) are derived from human amniotic epithelium.” NCT03381807 ↗ |
| Modality | Cell therapy | “Human amniotic epithelial stem cells (hAESCs) are derived from human amniotic epithelium.” NCT03381807 ↗ |
| Route | Other | “hAESCs is infused into uterine cavity after TCRA.” NCT03381807 ↗ |